Literature DB >> 19654082

[Interest of S100B protein blood level determination for the management of patients with minor head trauma].

D Bouvier1, C Oddoze, D Ben Haim, F Moustafa, A Legrand, M Alazia, E Jehle, J Schmidt, V Sapin.   

Abstract

Indication of cranial computed tomography (CCT) for patients with head minor injury (MHI) is difficult. Actually, 90% of patients with MHI who have CCT under the present clinical decision rules have normal scans. Serum concentrations of the protein S-100B were recently found to provide useful information. We have investigated whether S-100B concentrations in patients with MHI can provide additional information to improve indication of the need for an initial CCT scan. One hundred five patients with MHI were enrolled in this prospective study, at the French university hospital of Marseille and Clermont-Ferrand. Of the 105 patients studied, 16 exhibited trauma-relevant intracerebral lesions on the CCT scan (CCT+). With a cut-off limit of 0,10 microg/L S-100B, CCT+ patients were identified with a sensitivity level of 100% and a specificity level of 33%. Adding the measurement of S-100B serum concentration to the clinical decision rules for a CCT scan in patients with MHI could allow a 30% reduction in scans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654082     DOI: 10.1684/abc.2009.0347

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  6 in total

1.  Validity of Serum miRNA 93 and miRNA 191 to Reduce Unnecessary Computed Tomography in Patients With Mild Head Trauma.

Authors:  Demet Tas; Onur Kaplan; Ozgur Sogut
Journal:  J Clin Med Res       Date:  2020-08-15

2.  Classification accuracy of serum Apo A-I and S100B for the diagnosis of mild traumatic brain injury and prediction of abnormal initial head computed tomography scan.

Authors:  Jeffrey J Bazarian; Brian J Blyth; Hua He; Sohug Mookerjee; Courtney Jones; Karin Kiechle; Ryan Moynihan; Susan M Wojcik; William D Grant; LaLainia M Secreti; Wayne Triner; Ronald Moscati; August Leinhart; George L Ellis; Jawwad Khan
Journal:  J Neurotrauma       Date:  2013-08-24       Impact factor: 5.269

3.  The addition of S100B to guidelines for management of mild head injury is potentially cost saving.

Authors:  Olga Calcagnile; Anders Anell; Johan Undén
Journal:  BMC Neurol       Date:  2016-10-20       Impact factor: 2.474

4.  Assessment of the advantage of the serum S100B protein biomonitoring in the management of paediatric mild traumatic brain injury-PROS100B: protocol of a multicentre unblinded stepped wedge cluster randomised trial.

Authors:  Damien Bouvier; David Balayssac; Julie Durif; Charline Mourgues; Catherine Sarret; Bruno Pereira; Vincent Sapin
Journal:  BMJ Open       Date:  2019-05-24       Impact factor: 2.692

5.  Clinical validation of S100B use in management of mild head injury.

Authors:  Olga Calcagnile; Linda Undén; Johan Undén
Journal:  BMC Emerg Med       Date:  2012-10-27

6.  Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting to Emergency Departments with Mild Brain Injury: A Living Systematic Review and Meta-Analysis.

Authors:  Stefania Mondello; Abayomi Sorinola; Endre Czeiter; Zoltán Vámos; Krisztina Amrein; Anneliese Synnot; Emma Donoghue; János Sándor; Kevin K W Wang; Ramon Diaz-Arrastia; Ewout W Steyerberg; David K Menon; Andrew I R Maas; Andras Buki
Journal:  J Neurotrauma       Date:  2018-07-02       Impact factor: 5.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.